Skip to main content
Clinical Trials/NCT01860261
NCT01860261
Completed
Not Applicable

Pilot Study of the Effects of Exercise on Aging Among Older Persons With HIV

University of California, San Francisco1 site in 1 country34 target enrollmentJanuary 2013
ConditionsHIV

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
HIV
Sponsor
University of California, San Francisco
Enrollment
34
Locations
1
Primary Endpoint
VO2 max
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

This pilot study will test the feasibility and acceptability of a 12 week combined aerobic and strength training intervention among persons with HIV who are age 50 or older and do not exercise frequently, and its preliminary effects on aging-related outcomes . The study uses an randomized, controlled trial design and is intended to lead to a larger clinical trial with long-term follow-up. The intervention incorporates small group instruction from a trainer, a small wearable accelerometer to provide accurate data on physical activity, and real-time feedback to participants about exercise levels. The primary outcome measure will be changes in fitness, measured as change in maximal oxygen consumption (VO2 max). The control group will receive a comparable exercise intervention after they complete 12 weeks of observation.

Detailed Description

Approximately 40 individuals with HIV infection of at least 6 months duration who currently exercise infrequently will be randomized in a 2:1 ratio to either Intervention Arm (immediate exercise intervention program for 12 weeks duration), or the Control Arm (observation only for 12 weeks duration followed by treatment onset after observation is completed). Persons assigned to the Intervention Arm will meet initially once per week with a personal trainer, and once per week in small groups with a personal trainer, for a total of two weekly sessions of assisted strength training. In addition, participants will be encouraged to engage in three sessions of aerobic exercise per week of gradually increasing intensity of about 40 minutes duration each, for the 12 week intervention period. Instruction in walking and running form and body awareness that may reduce the risk of injuries (ChiWalking and ChiRunning technique) will be provided to the Intervention Arm by a certified coach during three sessions over the course of the 12 week intervention period as part of the aerobic exercise plan. Paid gym memberships will be provided for the 12 week treatment period for both groups (memberships for participants assigned to the Control Arm will not begin until the end of the 12 week observation period). Data will be collected for strength training activity using the passive FitLinxx system at the study gym, and for aerobic steps and pace using accelerometers (Pebble by FitLinxx). Participants in both groups will be asked to wear accelerometers for the duration of the study period. Participants will be evaluated at baseline, week 6 and week 12 for changes in lab values and questionnaire items. Change in fitness will be assessed using V02 max at baseline and week 12.

Registry
clinicaltrials.gov
Start Date
January 2013
End Date
August 2013
Last Updated
2 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • HIV-positive
  • Age \>=50 years on date of enrollment visit
  • Less than 60min/week of vigorous exercise on average in the 90d prior to enrollment
  • Able to complete study documents and activities in English (in this pilot we are only prepared to use English language questionnaires and instructional materials)
  • Interested in and willing to do an exercise program
  • Receiving continuous antiretroviral therapy (ART) for at least six months with an undetectable viral load at most recent clinic visit, or if not on ART then must have been off continuously for six months with no plan to start ART and have CD4 count \> 400 cells/µl (to avoid enrolling patients at risk of developing opportunistic infections or other HIV-associated illnesses).

Exclusion Criteria

  • Medical conditions likely to limit the ability to participate in the planned exercise, including renal failure (creatinine \> 2 mg/dl, congestive heart failure, significant lung disease, or severe osteoarthritis, Any health condition(s) that the study physician determines would preclude safe participation in the intervention or may require special modification of the exercise protocol (e.g. angina or myocardial infarction in the past 6 months)
  • Substantial deconditioning or current impairment of physical function; this will be tested for by assessing whether patients can climb up and back down one flight of stairs (approximately 3 meters of elevation gain) without stopping
  • Unable or unwilling to actively participate in the intervention for the duration of the pilot study
  • Unable to provide informed consent.

Outcomes

Primary Outcomes

VO2 max

Time Frame: 12 weeks (baseline to exit)

Fitness will be assessed by maximal oxygen consumption (V02max) during a stationary bike test, to be completed at baseline and repeated 12 weeks later at the exit visit.

Secondary Outcomes

  • Average distance walked/run per week(From baseline to week 12)
  • Injuries(From study baseline to week 12)
  • C-reactive protein(Six weeks (baseline to week 6) and 12 weeks (baseline to exit))
  • METs(12 weeks (baseline to exit))
  • Acceptability of study materials(Six months (01Jan2013 - 30June2013))
  • Self-reported physical activity(Change from week 0 to week 12)
  • NIH PROMIS 29(6 weeks (baseline to week 6) and 12 weeks (baseline to exit))
  • Feasibility of recruitment(11 weeks (01Jan2013 to 14Mar2013))

Study Sites (1)

Loading locations...

Similar Trials